Key Highlights
- KeyBanc initiates Overweight rating on RKLB with $135 price target, suggesting approximately 40% potential upside
- Nasdaq-100 Index addition confirmed for June 22, 2026
- Neutron rocket program stays on track for inaugural launch this year following successful resolution of January testing issue
- First quarter revenue reached $200.35 million, reflecting 63.4% year-over-year growth and exceeding Wall Street projections of $189.65 million
- Institutional investors control 71.78% of shares, with several major funds expanding positions during Q1
Rocket Lab (RKLB) shares are changing hands at $102.39, climbing 6.50% during Monday’s session as Wall Street recognition and index promotion drive renewed investor enthusiasm.
KeyBanc initiated coverage with an Overweight rating and established a $135 price objective. This target implies approximately 40% appreciation potential from current trading levels. The investment bank maintained its existing financial projections.
This positive analyst action arrives as Rocket Lab gears up for its Nasdaq-100 debut on June 22. Such index additions typically generate significant buying activity from the more than 200 exchange-traded products and mutual funds tracking the benchmark, which manage combined assets exceeding $800 billion.
KeyBanc highlighted Rocket Lab’s standing as the commercial space launch industry’s second-largest competitor. The company’s Electron launch vehicle has successfully completed approximately 90 missions to date.
For many market participants, the Neutron rocket program represents the more compelling growth narrative. KeyBanc noted improved transparency regarding the initiative over recent months and verified that a testing setback encountered in January has been completely addressed. The Neutron program remains aligned with its timeline for an inaugural flight before year-end.
Stifel recently increased its RKLB price objective to $132 from $110, reaffirming its Buy recommendation based on robust revenue trajectory and growing contract backlog.
First Quarter Performance Exceeds Expectations
On May 7, Rocket Lab disclosed Q1 revenue totaling $200.35 million, surpassing analyst projections of $189.65 million. This figure represented a 63.4% increase compared to the prior-year quarter.
Earnings per share registered at -$0.07, aligning with Street consensus. The organization recorded a net margin of negative 26.87% alongside a return on equity of negative 11.72%. Wall Street forecasts full-year EPS of -$0.29.
Shares have appreciated more than 300% over the trailing twelve months. The stock reached a 52-week peak of $151.00 and touched a low of $25.24, currently trading approximately 24% beneath its high-water mark. The 50-day moving average stands at $101.62.
Institutional Buying Activity Continues
Institutional investors control 71.78% of outstanding RKLB shares. During Q1, AQR Capital Management expanded its position by more than 100%, acquiring 92,849 additional shares. NewEdge Advisors increased its holdings by over 1,800%. UBS Asset Management purchased 90,758 shares, elevating its total stake to 773,548.
Entropy Technologies LP grew its investment by 18.5% in Q4, bringing its position to 55,117 shares valued at approximately $3.85 million.
Regarding insider transactions, Director Alexander Slusky divested 100,000 shares on May 12 at $118.08, trimming his ownership by 18.7%. Insider Marvin Bradford Clevenger sold 15,549 shares on May 26 at $142.57, with the transaction attributed to tax liabilities associated with vesting equity compensation.
Wall Street sentiment leans decidedly bullish. Among covering analysts, twelve assign Buy ratings, three recommend Strong Buy, five rate it Hold, and one suggests Sell. The average price target across analysts stands at $102.76.
The equity has also captured attention from heightened interest in space sector investments following SpaceX’s recent Nasdaq listing, with capital flowing into related aerospace companies.


